Press Releases

Press Releases

Year
News

19 February, 2020

Incyte Announces Launch of the Incyte Ingenuity Award Program to Recognize Innovation Within the GVHD Community

19 February, 2020

Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis

13 February, 2020

Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs

11 February, 2020

Incyte to Present at Upcoming Investor Conference

11 February, 2020

Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer

30 January, 2020

Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

28 January, 2020

Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis

27 January, 2020

Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine

23 January, 2020

Incyte to Report Fourth Quarter and Year-End Financial Results

13 January, 2020

MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

of 1 2 Next page

For Media Inquiries

Catalina Loveman Executive Director, Public Affairs

+1 302.498.6171 | media@incyte.com


For Investor Relations

Michael Booth, D.Phil.
Divisional VP of Investor Relations and Corporate Social Responsibility

Phone: 302.498.5914

Email: mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility

Phone: 302.498.6141

Email: layala@incyte.com

Christine Chiou
Senior Director, Investor Relations

Phone: 302.274.4773

Email: cchiou@incyte.com